标题
Desmoglein-2 as a prognostic and biomarker in ovarian cancer
作者
关键词
-
出版物
CANCER BIOLOGY & THERAPY
Volume 21, Issue 12, Pages 1154-1162
出版商
Informa UK Limited
发表日期
2020-11-21
DOI
10.1080/15384047.2020.1843323
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein‐2 cell entry receptor
- (2020) Lukasz Kuryk et al. JOURNAL OF MEDICAL VIROLOGY
- Upregulation of desmoglein 2 and its clinical value in lung adenocarcinoma: a comprehensive analysis by multiple bioinformatics methods
- (2020) Ruiying Sun et al. PeerJ
- Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma
- (2020) Runsen Jin et al. CANCER LETTERS
- Integrative prognostic subtype discovery in high‐grade serous ovarian cancer
- (2019) Hongyu Xie et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Junction opener protein increases nanoparticle accumulation in solid tumors
- (2018) Christine E. Wang et al. JOURNAL OF CONTROLLED RELEASE
- Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells
- (2017) Katharina Hütz et al. MOLECULAR CARCINOGENESIS
- Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells
- (2016) Kamola Saydaminova et al. CANCER BIOLOGY & THERAPY
- Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models
- (2016) Roma Yumul et al. HUMAN GENE THERAPY
- Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2
- (2016) Feng Cai et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- 193. Preclinical and Clinical Data with a Fully Serotype 3 Oncolytic Adenovirus Ad3-hTERT-E1A in the Treatment of Advanced Solid Tumors
- (2016) MOLECULAR THERAPY
- Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
- (2015) Steffen Ormanns et al. BRITISH JOURNAL OF CANCER
- Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1
- (2015) Hongjie Wang et al. JOURNAL OF VIROLOGY
- Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin
- (2015) Maximilian Richter et al. Molecular Therapy-Methods & Clinical Development
- Desmoglein 2 Depletion Leads to Increased Migration and Upregulation of the Chemoattractant Secretoneurin in Melanoma Cells
- (2014) Wiebke K. Peitsch et al. PLoS One
- Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer
- (2014) Alison G. Barber et al. PLoS One
- A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
- (2013) Kenneth H. Kim et al. GYNECOLOGIC ONCOLOGY
- Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling
- (2013) R Kamekura et al. ONCOGENE
- Phenotypic and Transcriptional Fidelity of Patient-Derived Colon Cancer Xenografts in Immune-Deficient Mice
- (2013) Jeffrey Chou et al. PLoS One
- Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs
- (2012) I. Beyer et al. CLINICAL CANCER RESEARCH
- A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses
- (2012) H. Wang et al. JOURNAL OF VIROLOGY
- Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer
- (2011) I. Beyer et al. CANCER RESEARCH
- Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125
- (2011) Michèl Schummer et al. GYNECOLOGIC ONCOLOGY
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
- (2011) Gordon John Sampson Rustin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions
- (2011) H. Wang et al. JOURNAL OF VIROLOGY
- Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity
- (2011) Robert Strauss et al. PLoS One
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
- (2010) Anniina Koski et al. MOLECULAR THERAPY
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
- (2010) Hongjie Wang et al. NATURE MEDICINE
- Increased expression of Dsg2 in malignant skin carcinomas
- (2010) Donna Brennan et al. Cell Adhesion & Migration
- Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses
- (2009) R. Strauss et al. CANCER RESEARCH
- Progress in Gynecologic Cancer
- (2009) Michael V. Seiden SEMINARS IN ONCOLOGY
- Physiology and Function of the Tight Junction
- (2009) J. M. Anderson et al. Cold Spring Harbor Perspectives in Biology
- Tight junctions as targets of infectious agents
- (2008) Julian A. Guttman et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers
- (2008) Cynthia Kuk et al. MOLECULAR & CELLULAR PROTEOMICS
- EGFR and ADAMs Cooperate to Regulate Shedding and Endocytic Trafficking of the Desmosomal Cadherin Desmoglein 2
- (2008) Jodi L. Klessner et al. MOLECULAR BIOLOGY OF THE CELL
- Desmosome structure, composition and function
- (2007) David Garrod et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now